View Future GrowthBio SolutionLtd 過去の業績過去 基準チェック /26Bio SolutionLtdの収益は年間平均-8.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.2% 10.6%割合で 増加しています。 Bio SolutionLtdの自己資本利益率は1.6%であり、純利益率は4.1%です。主要情報-8.62%収益成長率-6.57%EPS成長率Biotechs 業界の成長11.70%収益成長率10.65%株主資本利益率1.56%ネット・マージン4.14%前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesNew Risk • Jun 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩152.2b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩152.2b market cap, or US$99.0m).お知らせ • Mar 14Bio Solution Co.,Ltd., Annual General Meeting, Mar 27, 2026Bio Solution Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 232, gongneung-ro, nowon-gu, seoul South KoreaNew Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).New Risk • May 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change).お知らせ • Mar 15Bio Solution Co.,Ltd., Annual General Meeting, Mar 28, 2025Bio Solution Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 232, gongneung-ro, nowon-gu, seoul South KoreaNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).New Risk • May 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.2b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩137.2b market cap, or US$99.2m).New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change).New Risk • Jan 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩128.9b (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩128.9b market cap, or US$96.6m).New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩102.9b market cap, or US$78.0m).お知らせ • Sep 10Biosolution Co.,Ltd. (KOSDAQ:A086820) agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion.Biosolution Co.,Ltd. (KOSDAQ:A086820) agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion on September 9, 2021. Kyperion Co., Ltd reported total revenues of KRW 309 million, total assets of KRW 5 billion , net loss of KRW 1.2 billion and total common equity of KRW 3 billion for the financial year ending December 31, 2020. The deal is expected o be completed by September 13, 2021.お知らせ • Apr 18Biosolution Co.,Ltd. announced that it expects to receive KRW 80 billion in funding from Eum Private Equity, IBK Capital CorporationBiosolution Co.,Ltd. (KOSDAQ:A086820) announced a private placement of round 1 Unregistered coupon nonguaranteed private convertible bonds for gross proceeds of KRW 80,000,000,000 on April 16, 2021. The transaction will include participation from Eum Private Equity and IBK Capital Corporation. The bonds bear an interest rate and yield to maturity of 3%, are issued at par and will mature on July 16, 2026. The bonds are fully convertible into 2,638,696 common shares representing 32.61% stake at a conversion price of KRW 30,318 per share from July 18, 2022 to July 15, 2026. The transaction has been approved by the board of directors of the company. The bonds are subject to prohibition of events and divisions for more than one year. The subscription date is on April 20, 2021 and the payment date is on July 16, 2021.Is New 90 Day High Low • Feb 24New 90-day low: ₩26,100The company is down 14% from its price of ₩30,450 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: ₩31,650The company is up 14% from its price of ₩27,800 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 16New 90-day low: ₩24,000The company is down 14% from its price of ₩27,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: ₩26,200The company is down 17% from its price of ₩31,400 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period.収支内訳Bio SolutionLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A086820 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2615,8246557,0896,13431 Dec 2515,2002736,6026,30630 Sep 2514,369-10,4976,4196,05730 Jun 2513,290-11,1396,5215,42831 Dec 2412,889-11,9286,4215,75531 Mar 218,275-1,2833,4463,20831 Dec 207,744-1,8003,5343,23030 Sep 207,207-1,3762,7963,71930 Jun 207,331-1,6142,9023,85031 Dec 198,882-6983,3953,645質の高い収益: A086820には₩4.9B } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。利益率の向上: A086820過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A086820過去 5 年間で収益を上げており、収益は年間-8.6%増加しています。成長の加速: A086820は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: A086820昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 22.6% ) と比較することは困難です。株主資本利益率高いROE: A086820の 自己資本利益率 ( 1.6% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 02:04終値2026/07/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio Solution Co.,Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Eui-Seob ShimNH Investment & Securities Co., Ltd.
New Risk • Jun 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩152.2b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩152.2b market cap, or US$99.0m).
お知らせ • Mar 14Bio Solution Co.,Ltd., Annual General Meeting, Mar 27, 2026Bio Solution Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 232, gongneung-ro, nowon-gu, seoul South Korea
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
New Risk • May 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change).
お知らせ • Mar 15Bio Solution Co.,Ltd., Annual General Meeting, Mar 28, 2025Bio Solution Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 232, gongneung-ro, nowon-gu, seoul South Korea
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).
New Risk • May 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.2b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩137.2b market cap, or US$99.2m).
New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change).
New Risk • Jan 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩128.9b (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩128.9b market cap, or US$96.6m).
New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩102.9b market cap, or US$78.0m).
お知らせ • Sep 10Biosolution Co.,Ltd. (KOSDAQ:A086820) agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion.Biosolution Co.,Ltd. (KOSDAQ:A086820) agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion on September 9, 2021. Kyperion Co., Ltd reported total revenues of KRW 309 million, total assets of KRW 5 billion , net loss of KRW 1.2 billion and total common equity of KRW 3 billion for the financial year ending December 31, 2020. The deal is expected o be completed by September 13, 2021.
お知らせ • Apr 18Biosolution Co.,Ltd. announced that it expects to receive KRW 80 billion in funding from Eum Private Equity, IBK Capital CorporationBiosolution Co.,Ltd. (KOSDAQ:A086820) announced a private placement of round 1 Unregistered coupon nonguaranteed private convertible bonds for gross proceeds of KRW 80,000,000,000 on April 16, 2021. The transaction will include participation from Eum Private Equity and IBK Capital Corporation. The bonds bear an interest rate and yield to maturity of 3%, are issued at par and will mature on July 16, 2026. The bonds are fully convertible into 2,638,696 common shares representing 32.61% stake at a conversion price of KRW 30,318 per share from July 18, 2022 to July 15, 2026. The transaction has been approved by the board of directors of the company. The bonds are subject to prohibition of events and divisions for more than one year. The subscription date is on April 20, 2021 and the payment date is on July 16, 2021.
Is New 90 Day High Low • Feb 24New 90-day low: ₩26,100The company is down 14% from its price of ₩30,450 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: ₩31,650The company is up 14% from its price of ₩27,800 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 16New 90-day low: ₩24,000The company is down 14% from its price of ₩27,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: ₩26,200The company is down 17% from its price of ₩31,400 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period.